Rapid PMA (premarket approval application) review for Fusion's FloSeal:
This article was originally published in Clinica
The FDA has granted streamlined review status to Fusion Medical Technologies' premarket approval application (PMA) to market its FloSeal surgical sealant in the US. The product, a collagen-derived matrix with thrombin, was submitted to the FDA in February and the agency is currently targeting final approval decisions for PMA applications to be completed in 180 days, said the Mountain View, California-based company. Fusion CE-marked the bioresorbable haemostatic sealant for use in a broad range of surgical procedures last month.
You may also be interested in...
Trump administration effort to reduce drug prices by curtailing agency program requiring new approvals for some old products undermines FDA’s role in policing the safety of prescription drugs, experts say.
The maker of prestige-inspired cosmetics at value prices follows its TikTok viral success by teaming with Kathleen Belsten, aka Loserfruit, the second most-followed female gamer on the Amazon-owned livestreaming platform Twitch.
As distribution of Regeneron’s monoclonal antibody treatment for coronavirus begins, OWS officials worry about provider confusion with Lilly’s product due to differences in preparation and administration.